Claims for Patent: 11,654,139

Summary for Patent: 11,654,139

Title:	Anti-infective methods, compositions, and devices
Abstract:	The present invention provides methods for treating onychomycosis. In certain embodiments, the methods comprise comprising applying a pharmaceutically acceptable formulation containing 10% efinaconazole once a day for a treatment period of at least 36 weeks to the treatment area of an onychomycosis patient (a) without debriding the nail or nail-associated tissue initially or during the treatment period and/or (b) without removing the formulation from the treatment area during the treatment period. In certain embodiments, the formulation also comprises, water, cyclomethicone, diisopropyl adipate, alcohol, C12-15 alkyl lactate, butylated hydroxytoluene, citric acid anhydrous, and disodium edetate.
Inventor(s):	Radhakrishnan Pillai, Gordon Dow
Assignee:	Bausch Health Ireland Ltd
Application Number:	US17/062,973
Patent Claims:	1. A method for treating onychomycosis comprising: (a) providing a container that is suitable for storing an efinaconazole formulation for pharmaceutical use that comprises an applicator that is capable of dispensing a pharmaceutically effective dose of the efinaconazole formulation and spreading an approximately uniform amount of the efinaconazole formulation to a treatment area of a toenail to be treated by manual action after loading, (b) loading the applicator with the dose of the efinaconazole formulation, wherein the formulation comprises 10% w/w efinaconazole, alcohol, cyclomethicone, diisopropyl adipate, either or both of C12-15 alkyl lactate and isopropyl myristate, an antioxidant, butylated hydroxytoluene (BHT), and a salt of disodium edetate ethylenediaminetetraacetic acid (EDTA), and (c) administering the dose of the efinaconazole formulation to the treatment area of the toenail to be treated by uniform manual spreading. 2. The method of claim 1, wherein the container is a multiple use container and the method comprises repeating steps (a)-(c) of the method for the treatment area of the toenail to be treated once a day for at least 4 weeks. 3. The method of claim 1, wherein the method comprises manually loading of the applicator with the dose of the efinaconazole formulation. 4. The method of claim 3, wherein the container is a squeeze sensitive container and the applicator is a flow through applicator which delivers the efinaconazole formulation to the treatment area of the toenail to be treated when a user applies sufficient pressure on the container. 5. The method of claim 1, wherein the method is performed for at least 36 weeks. 6. The method of claim 5, wherein the method is performed for 48 weeks. 7. The method of claim 1, wherein the applicator is selected from the group consisting of a brush, a pad, a swab, a sponge, or a roller. 8. The method of claim 1, wherein the volume of efinaconazole formulation contained in the applicator is about 75 to about 150 microliters. 9. The method of claim 1, wherein the method comprises cutting the toenail to be treated once every two weeks or more frequently. 10. The method of claim 1, wherein the method does not comprise cutting the toenail to be treated more often than every two weeks. 11. The method of claim 1, wherein the efinaconazole formulation is not administered in an occluded or semi-occluded manner. 12. The method of claim 1, wherein the efinaconazole formulation is administered without debriding the nail or nail-associated tissue of the toenail to be treated initially or during the treatment period. 13. The method of claim 1, wherein the efinaconazole formulation is administered without removing the formulation from the treatment area of the toenail to be treated during the treatment period. 14. The method of claim 1, wherein the formulation further comprises water. 15. The method of claim 1, wherein the average amount of efinaconazole delivered to each cm2 of the treatment area of the toenail to be treated is about 0.15 mg/cm2 to about 0.45 mg/cm2. 16. The method of claim 1, wherein performance of the method in a patient population results in a mycological cure rate of at least about 40%, a clinical efficacy rate of at least about 20%, a complete cure rate of at least about 10%, or a combination of any or all thereof. 17. The method of claim 1, wherein the efinaconazole formulation is administered to the treatment area of each toenail of a subject by uniform manual spreading. 18. The method of claim 17, wherein the subject is a human subject. 19. The method of claim 18, wherein the efinaconazole formulation is administered to the treatment area of each toenail of the human subject.